People · Operator
Named in public records as an officer, director or promoter · active 2020–2020 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Mereo Biopharma Group plc | — | Pharmaceuticals | Series C | $70.0M | $2.5B | 2020 |
Dr. Denise Scots-Knight at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Dr. Denise Scots-Knight on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Wyzga | 1 | 5 |
| Richard Jones | 1 | 4 |
| John Richard | 1 | 2 |
| Paul Blackburn | 1 | 1 |
| Jill Henrich | 1 | 1 |
| Charles Sermon | 1 | 1 |
| Peter Bains | 1 | 1 |
| Dr. Anders Ekblom | 1 | 1 |
| Dr. Deepa Pakianathan | 1 | 1 |
| Dr. Alastair MacKinnon | 1 | 1 |
| Dr. Peter Fellner | 1 | 1 |
| Kunal Kashyap | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.